For instance, Luteolin, a honeysuckle flavonoid, acts as a partial agonist/antagonist on PPARγ, inhibiting some target genes and adipogenesis while activating GLUT4 like rosiglitazone; in IBD, it uniquely binds to PPARγ without stabilizing the activation helix, providing significant anti-inflammatory effects without promoting adipocyte differentiation, making it a safer alternative to thiazolidinediones (TZDs) for treating other inflammatory conditions such as type II diabetes (204). This evidence concerns the gene PPARG and inflammatory bowel disease.